Business Wire

New Product From SugarCRM Provides Key Customer Data During Real-Time Communications

26.9.2019 18:00:00 EEST | Business Wire | Press release

Share

SugarCRM Inc.®, a company that helps organizations deliver exceptional customer experiences, today announced Sugar Connect, its latest product innovation designed to improve end-user adoption of CX solutions through simplification, integration and the application of the company’s no-touch philosophy.

Sugar Connect provides sales and customer service representatives critical contextual information about customers when and where they need it most: when they’re communicating with them in real-time and from right within the tool they use most - email.

With Sugar Connect, users can access all customer account information from within Microsoft Office 365 or Google G Suite, eliminating the need to switch between apps, search for needed customer information, or copy and paste data between their office productivity apps and Sugar.

“One of the biggest reasons customer experience solutions fail is because they require so much of the end user,” said Sugar Chief Product Officer, Rich Green. “We’ve removed the tedious work and embedded CX capabilities where they can provide the most value, which is a direct result of qualitative and quantitative information we’ve received from our customers.”

Sugar Connect synchronizes data directly with Sugar Sell and Sugar Serve, incorporating email, calendar events, tasks and contacts into the unified customer view, provided by the Sugar platform. This integration solves common issues such as tab fatigue, missing records and poor follow-up, which will ultimately increase sales, productivity and win-rates and decrease the time it takes to resolve support cases.

“Our mission is to help our clients create customers for life,” added Sugar CEO Craig Charlton. “A big part of fulfilling that mission is removing barriers that impede adoption of CX solutions. By embedding CX into the most commonly used apps, Sugar Connect will do just that.”

Other features and benefits of Sugar Connect include:

  • 360-Degree Customer View: Gain complete visibility into the health of your accounts, contacts, leads, and opportunities from within your email app
  • Automated Data Entry: Archive important emails to Sugar, while automatically syncing your calendar and contacts
  • Effortless CRM: Access and update Sugar, without leaving your email app
  • Scheduling Assistant: Easily schedule meetings with your customers' without the back-and-forth

“Sugar Connect is the perfect example of No-Touch Information Management in action,” added Green. “It captures information as the user engages with customers and then enriches that data with information from third-party data services, AI-based insights, and next best action guidance, providing key insights just when they need them.”

About SugarCRM

SugarCRM is a customer experience leader enabling businesses to create profitable customer relationships by delivering highly relevant, personalized experiences throughout the customer journey. We empower companies to strengthen existing customer relationships, create new ones through actionable insights and intelligent automation and better understand the customer at every stage of the journey. This enables businesses to accelerate demand generation, grow revenue, deliver superior customer care and increase loyalty. Our easy-to-use, intuitive platform makes customer experience easy and accessible for everyone, allowing marketing, sales and services professionals to focus on high-impact, value-added activities that create customers for life.

Based in Silicon Valley, SugarCRM is backed by Accel-KKR. More than 2 million individuals in over 120 countries rely on SugarCRM.

For more information about Sugar Connect, visit the website at www.sugarcrm.com or follow @SugarCRM.

NOTE: SugarCRM and the SugarCRM logo are registered trademarks of SugarCRM Inc. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Angela Connor
Change Agent Communications
angela@changeagentcommunications.com
919-635-8527

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release

Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob

Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release

Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati

Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release

Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye